Human CAP cells represent a novel source for functional, miRNA-loaded exosome production

Area of Science:

• Biotechnology
• Cell Biology
• Nanomedicine

Background:

• Exosomes are natural nanovesicles with potential for drug delivery.
• Current limitations exist in producing exosomes from non-tumorigenic sources for therapeutic miRNA delivery.
• Exosomes protect nucleic acids and facilitate cellular uptake.

Purpose of the Study:

• To engineer a non-tumorigenic cell line for efficient exosome production.
• To characterize exosomes derived from the engineered cell line for miRNA loading.
• To evaluate the therapeutic potential of miRNA-loaded exosomes in cancer cells.

Main Methods:

• Immortalized human amniocyte cell line (CAP® cells) engineering.
• Exosome enrichment and characterization (GFP labeling).
• Loading of pro-apoptotic microRNAs into exosomes.
• Co-culture experiments with ovarian cancer cells.
• Gene expression analysis of target genes in tumor cells.

Main Results:

• Engineered CAP cells produced functional exosomes without affecting cell growth.
• CAP cell-derived exosomes efficiently delivered pro-apoptotic miRNAs to ovarian cancer cells.
• Delivered miRNAs led to the downregulation of target genes in cancer cells.
• Demonstrated uptake of miRNA-containing exosomes by tumor cells.

Conclusions:

• CAP cells are a novel and efficient host for producing functional miRNA-loaded exosomes.
• This platform offers potential for developing nucleic acid-based therapeutics.
• Non-tumorigenic exosome production is feasible for pharmaceutical applications.